Drug Database
Back to search

Poland· PL-100393054

Erlotinib SUN

A erlotinib product containing erlotinibum, registered in Poland by Sun Pharmaceutical Industries Europe B.V.. The same ATC class is registered in 2 of our 19 countries.

ATC L01XE03

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedErlotinib SUNATCL01XE03REGISTER NO.PL-100393054PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about erlotinibumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Erlotinib is registered in 2 of 19 countries.

Countries holding a registration under ATC L01XE03 (erlotinib), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 2 of them publish a price we can compare per daily dose
Search erlotinib products by name

Erlotinib · ATC L01XE03

2 / 19 countries

  • Belgiumprice
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Erlotinibum
Manufacturer
Sun Pharmaceutical Industries Europe B.V.
Country
Poland (PL)
ATC code
L01XE03
ATC class
Erlotinib
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909991407612
  • gtin
    05909991407629

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

355 interactions on record for erlotinib.

Graded by severity as the source publishes them — 14 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check erlotinib against other medicinesHow interaction checks work

Erlotinib · interactions on record

355 records

  • 14 severe
  • 192 moderate
  • 2 minor
  • 147 info

Most severe, free to view

  • OmeprazoleA02BC01severe
  • PantoprazoleA02BC02severe
  • LansoprazoleA02BC03severe
  • RabeprazoleA02BC04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Erlotinib in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All erlotinib products

Authorised across Europe · EMA

The same active substance is authorised in 26 EEA countries. Names it is sold under:

  • Belgium · Erlotinib Sandoz
  • Bulgaria · Ерлотиниб Актавис, Ерлотиниб Крка
  • Cyprus · Erlotinib Remedica
  • Czechia · Erlotinib Krka, Erlotinib Teva
  • Germany · Erlotev, Erlotinib Axiromed
  • Denmark · Erlotinib "stada", Erlotinib Krka
  • Estonia · Erlotinib Viatris
  • Spain · Erlotinib Sandoz, Erlotinib Tarbis
  • Finland · Erlotinib Krka, Erlotinib Stada
  • France · Erlotinib Biogaran, Erlotinib Eg
  • United Kingdom (Northern Ireland) · Erlotinib Amarox, Erlotinib Glenmark
  • Greece · Erlotinib Faran, Erlotinib Teva
  • Croatia · Erlotinib Alpha-Medical, Erlotinib Krka
  • Hungary · Erlotinib Actavis, Erlotinib Krka
  • Iceland · Erlotinib Krka, Erlotinib Teva
  • Italy · Erlotinib Mylan, Erlotinib Sandoz
  • Liechtenstein · Tarceva
  • Lithuania · Erlotinib Viatris, Varlota
  • Latvia · Erlotinib Sandoz, Erlotinib Viatris
  • Netherlands · Erlotinib Accordpharma, Erlotinib Amarox
  • Norway · Erlotinib Krka, Tarceva
  • Portugal · Erlotinib Mylan, Erlotinib Qritou
  • Romania · Erlotinib Krka, Erlotinib Viatris
  • Sweden · Erlotinib Krka, Erlotinib Medical Valley
  • Slovenia · Erlotinib Krka, Erlotinib Teva
  • Slovakia · Erlotinib Sandoz, Erlotinib Stada

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/6d48d038-70bf-471c-bb87-ad8f972890cb
GET /v1/drugs/6d48d038-70bf-471c-bb87-ad8f972890cb?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "100 mg",
  "packaging": "05909991407612 ¦ Rpz ¦ 133173\n30 tabl.\n05909991407629 ¦ Rpz ¦ 133174\n30 tabl.",
  "substance": "Erlotinibum 100 mg",
  "common_name": "Erlotinibum",
  "pl_product_id": "100393054",
  "pozwolenie_nr": "25481",
  "auth_procedure": "DCP",
  "authorisation_validity": "2024-07-22"
}
API referenceMCP serverPlans

See everything about erlotinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console